These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 12619112)

  • 1. TP53 mutation in colorectal cancer.
    Iacopetta B
    Hum Mutat; 2003 Mar; 21(3):271-6. PubMed ID: 12619112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
    Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
    Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
    Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
    Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
    J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
    Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
    Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
    Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
    Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [p53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis].
    Yang Y; Xia Q; Lian F
    Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):114-8. PubMed ID: 11776850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers.
    Huang CC; Cheng YW; Chen MC; Lin YS; Chou MC; Lee H
    Environ Mol Mutagen; 2006 Aug; 47(7):527-32. PubMed ID: 16721749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
    Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
    J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [p53 mutations in sporadic colorectal cancers with microsatellite instability].
    Huang J; Zheng S; Pan QR; Deng YC
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1130-3. PubMed ID: 12921629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
    Ott K; Vogelsang H; Mueller J; Becker K; Müller M; Fink U; Siewert JR; Höfler H; Keller G
    Clin Cancer Res; 2003 Jun; 9(6):2307-15. PubMed ID: 12796400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.
    Børresen-Dale AL; Lothe RA; Meling GI; Hainaut P; Rognum TO; Skovlund E
    Clin Cancer Res; 1998 Jan; 4(1):203-10. PubMed ID: 9516972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.